Litcius/Paper detail

Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia

William L. Conte

2020Multiple Sclerosis and Related Disorders32 citationsDOIOpen Access PDF

Topics & Concepts

OcrelizumabMedicineRituximabRheumatoid arthritisMultiple sclerosisInternal medicineImmunologyAntibodySARS-CoV-2 and COVID-19 ResearchPeripheral Neuropathies and DisordersRheumatoid Arthritis Research and Therapies
Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia | Litcius